Affinia Therapeutics

We had a successful Cell & Gene Meeting on the Mesa 2025 conference last week! Affinia’s Chief Business and Financial Officer Rami Daoud and Alanna Murday, Corporate Strategy and Business Development, participated in great scientific exchange about the latest advances in cell and #genetherapy and celebrated our Series C announcement. It was wonderful to see many peers and former colleagues and make new acquaintances. #rationallydesignedcapsids

Affinia looks forward to participating at several upcoming investor conferences. CEO Rick Modi will participate in a panel and management will participate in one-on-one investor meetings at the Chardan 9th Annual Genetic Medicines Conference being held October 21, 2025 in New York, NY. Rick’s panel, “In Vivo Gene Therapies for Genetic Cardiac Diseases,” takes place at 12pET. Affinia’s management will also participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference – London being held November 17-20, 2025. https://bit.ly/4n4UMk6 #rationallydesignedcapsids #geneticmedicines

Affinia is pleased to announce the close of a $40 million Series C financing. The financing was led by New Enterprise Associates (NEA) with participation from new investor, Eli Lilly and Company, and existing investors Alexandria Venture Investments, LLC, Atlas Venture, Avidity Partners, F-Prime, GV (Google Ventures), Mass General Brigham Ventures, and Perceptive Advisors. The proceeds from the financing will fund development of our lead program, AFTX-201, a potential first-in-class and best-in-class investigational #geneticmedicine for the treatment of BAG3 dilated cardiomyopathy (DCM). In addition, the financing will support the advancement of Affinia’s gene therapy pipeline of novel product candidates in additional devastating diseases. Rick Modi, Affinia’s CEO said, “We are grateful to this outstanding group of institutional and strategic investors who share our excitement about our novel, cardiotropic capsids and pipeline. This financing recognizes the potential of our novel capsids and the value of our lead program AFTX-201, bringing it one step closer to potentially become the first-in-class and best-in-class genetic medicine to treat #BAG3DCM.” #rationallydesignedcapsids https://bit.ly/3KC02OF

Affinia is looking forward to attending the Cell & Gene Meeting on the Mesa 2025 conference being held next week, October 6-8, in Phoenix. Meeting on the Mesa is the sector’s foremost annual conference bringing together senior leaders in the industry to advance leading-edge cell and #genetherapy research into cures. https://lnkd.in/eiUpMy4 #rationallydesignedcapsids

Affinia’s CEO Rick Modi is featured in this month’s PharmaShots CXO podcast with editor-in-chief Aditya Singh. Rick talks about his personal journey in the field of #geneticmedicine, what differentiates Affinia from other #genetherapy companies, the unmet medical need in #BAG3 dilated cardiomyopathy (#DCM), and the discovery and development of the company’s lead program, AFTX-201, a potential first-in-class and best-in-class genetic medicine for the treatment of BAG3 DCM. BAG3 DCM is a serious, inherited heart condition with a high mortality rate and a large unmet medical need. #rationallydesigned https://bit.ly/3Io8WOZ  

We’re proud to spotlight Affinia Therapeutics, a trailblazing #GeneTherapy company, for their commitment to environmental stewardship through Polycarbin's #ClosedLoop #recycling solution. By diverting their single-use lab plastics from landfill and incineration, Affinia is closing the loop on waste while continuing to push the boundaries of #GeneticMedicine. What’s more, Affinia is doing it with the support of INTEGRA Biosciences, whose pipetting products are a model for sustainable design and end-of-life circularity. As a brand partner, Integra continues to champion recyclable, high-performance labware that helps our customers meet their ESG goals without compromising on precision. This is the kind of collaboration that moves our industry, and our planet, forward.  Science, sustained.  Powered by Polycarbin. #SustainableScience #LabSustainability #CircularEconomy 

Affinia is proud to announce that we have joined forces with the DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium (GCAC) to raise awareness about #BAG3 dilated cardiomyopathy (#DCM), with the goal of promoting early diagnosis and the critical need for #genetictesting. #BAG3DCM is a devastating monogenic heart disease with a known genetic cause that affects more than 70,000 patients in the U.S., Europe, and U.K. regions alone. Hideo Makimura, M.D., Ph.D., Affinia’s CMO, said, “Unfortunately, only a fraction of patients affected with BAG3 DCM and other genetic cardiomyopathies are tested, which is putting lives at risk. We are committed to working together with the DCM Foundation and GCAC to increase disease awareness and the role genetics plays in cardiomyopathy, which we believe will ultimately lead to better outcomes for people living with BAG3 DCM.” Affinia’s CEO Rick Modi commented, “Our partnership with the DCM Foundation and GCAC is an exciting milestone as we advance our lead program, AFTX-201 for BAG3 DCM, toward an IND submission and clinical trial initiation which are aligned with Affinia’s purpose to make a lasting positive impact in the lives of people affected by devastating rare and prevalent diseases where the genetic cause is understood.” https://bit.ly/43twaLr #rationallydesignedcapsids #geneticmedicine #genetherapy

Affinia is proud to announce that we have joined forces with the DCM Foundation and the Genetic Cardiomyopathy Awareness Consortium (GCAC) to raise awareness about #BAG3 dilated cardiomyopathy (#DCM), with the goal of promoting early diagnosis and the critical need for #genetictesting. #BAG3DCM is a devastating monogenic heart disease with a known genetic cause that affects more than 70,000 patients in the U.S., Europe, and U.K. regions alone. Hideo Makimura, M.D., Ph.D., Affinia’s CMO, said, “Unfortunately, only a fraction of patients affected with BAG3 DCM and other genetic cardiomyopathies are tested, which is putting lives at risk. We are committed to working together with the DCM Foundation and GCAC to increase disease awareness and the role genetics plays in cardiomyopathy, which we believe will ultimately lead to better outcomes for people living with BAG3 DCM.” Affinia’s CEO Rick Modi commented, “Our partnership with the DCM Foundation and GCAC is an exciting milestone as we advance our lead program, AFTX-201 for BAG3 DCM, toward an IND submission and clinical trial initiation which are aligned with Affinia’s purpose to make a lasting positive impact in the lives of people affected by devastating rare and prevalent diseases where the genetic cause is understood.” https://bit.ly/43twaLr #rationallydesignedcapsids #geneticmedicine #genetherapy

It was a fantastic #ASGCT25! New preclinical data on AFTX-201, Affinia’s lead program for #BAG3 dilated cardiomyopathy (#DCM), as well as data on our novel #AAV capsids for diseases of the #CNS, and our high-yield manufacturing process, were featured in several oral and poster presentations at #ASGCT25. AFTX-201, a potential best-in-class investigational gene therapy intended to be given as a simple one-time IV administration, is undergoing #IND-enabling studies and Affinia is on track to submit an IND for AFTX-201 in 4Q25 with initial readouts of clinical trial efficacy and safety in 1H26. It was great to connect with friends and meet new colleagues who are working to advance potential new and transformative gene and cell therapies. From l-to-r: John Reece-Hoyes, Matt Edwards, Giri Murlidharan #rationallydesignedcapsids #genetherapy